IP Library Granted Patent US 11,459,292
Granted Patent B2
US 11,459,292 · App. 17/407,394 · Granted Oct 4, 2022

Metal salts and uses thereof

Inventors: Stephen Wald (Woodcliff Lake, NJ); Eduardo J. Martinez (Bryn Mawr, PA); Samuel Stratford (Cambridge, GB); Amanda Buist (Cambridge, GB); Joseph Benson (Edinburgh, GB); Jonathan Loughrey (Edinburgh, GB)
Assignee: Inspirna, Inc.
C07C229/34A61P35/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,459,292
App. No.
17/407,394
Granted
Oct 4, 2022
Kind
B2
Abstract

The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.

Claims (5)

1. A pharmaceutical composition for oral administration comprising (i) a zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid (Compound1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt, and (ii) a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of an emulsion, an aqueous suspension, a dispersion, or a solution.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is in unit dosage form.

4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is in unit dosage form a capsule or a tablet.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is a unit dosage form comprising a solution of the zinc salt.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: BENSON, JOSEPH; LOUGHREY, JONATHAN
To: SOLID FORM SOLUTIONS LIMITED
Reel/Frame 057964/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: STRATFORD, SAMUEL; BUIST, AMANDA
To: JOHNSON MATTHEY PLC
Reel/Frame 057964/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: JOHNSON MATTHEY PLC
To: RGENIX, INC.
Reel/Frame 057964/0638 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: SOLID FORM SOLUTIONS LIMITED
To: RGENIX, INC.
Reel/Frame 057964/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2021
From: WALD, STEPHEN; MARTINEZ, EDUARDO J.
To: RGENIX, INC.
Reel/Frame 057964/0882 →
CHANGE OF NAME Recorded Sep 17, 2021
From: RGENIX, INC.
To: INSPIRNA, INC.
Reel/Frame 057537/0973 →
Continuity (3)
Continuation 17119527 · Dec 11, 2020
Provisional Application 62947968 · Dec 13, 2019
Related Publication 20220041541A1 · Feb 10, 2022
Cited By (1)
US 12,258,303